Shivani Srivastava, PhD
Associate Research ScientistDownloadHi-Res Photo
Cards
Appointments
Contact Info
About
Copy Link
Titles
Associate Research Scientist
Biography
Shivani Srivastava earned her Ph.D. in Biochemistry from Banaras Hindu University in India, where her doctoral research focused on the mechanisms of diabetes—specifically beta-cell adaptation, incretin biology, and phytotherapeutics. This foundational work sparked her enduring interest in metabolic disease biology.
In 2020, she moved to the United States to pursue postdoctoral research at The Ohio State University and UCLA, gaining extensive technical expertise and a broader understanding of the interplay between metabolic and cardiovascular health. She later joined Dr. Demetrios Braddock’s lab in the Department of Pathology at Yale University and contributed to research on rare diseases and metabolic disorders, including Hutchinson-Gilford progeria syndrome, hearing loss, ossification of the posterior longitudinal ligament (OPLL), and childhood obesity.
By studying disease mechanisms in preclinical models, her work aims to bridge basic science and clinical translation in the field of bone diseases, diabetes, and obesity.
Last Updated on December 23, 2025.
Appointments
Cellular & Molecular Physiology
Associate Research ScientistPrimary
Other Departments & Organizations
Education & Training
- Postdoctoral Associate
- School of Medicine, Yale University, USA
- Postdoctoral Scholar
- David Geffen School of Medicine, UCLA, USA
- Postdoctoral Scholar
- Wexner Medical Center, OSU, USA
- PhD
- Institute of Medical Sciences, BHU, India
Research
Copy Link
Overview
Medical Research Interests
Bone Diseases; Diabetes Complications; Diabetes Mellitus; Obesity
ORCID
0000-0001-8042-4476
Publications
Featured Publications
The prevalence of ENPP1 deficiency in humans with OPLL and the preclinical efficacy of ENPP1 enzyme therapy in OPLL mice.
Srivastava S*, Kato H*, von Kroge S*, Weise K, Stabach P, Lopez SG, O'Brien K, Lester ER, Kim H, Ishaq T, Dammen-Brower K, Schinke T, Kimura S, Miyahara J, Doi T, Oshima Y, Yarema KJ, Carpenter TO, Sabbagh Y, Tommasini SM, Ito N, Oheim R, Braddock DT. The prevalence of ENPP1 deficiency in humans with OPLL and the preclinical efficacy of ENPP1 enzyme therapy in OPLL mice. Journal of Bone and Mineral Research. 2025 PMID: 41251406, DOI: 10.1093/jbmr/zjaf168.Peer-Reviewed Original ResearchImprovements in hearing loss with bone-targeted enzyme replacement therapy are associated with corrected hypomineralization and osteocyte properties of auditory ossicles in Enpp1-deficient mice.
Ocokoljic A*, Srivastava S*, von Kroge S, Stabach PR, Busse B, Weise K, Oheim R, Rolvien T†, Braddock DT†. Improvements in hearing loss with bone-targeted enzyme replacement therapy are associated with corrected hypomineralization and osteocyte properties of auditory ossicles in Enpp1-deficient mice. Journal of Bone and Mineral Research. 2025;40(9):1077–1086. PMID: 40495691, DOI: 10.1093/jbmr/zjaf082.Peer-Reviewed Original ResearchExpression kinetics reveal the self-adaptive role of β cells during the progression of diabetes
Srivastava S, Pandey H, Tripathi Y. Expression kinetics reveal the self-adaptive role of β cells during the progression of diabetes. Biomedicine & Pharmacotherapy 2018, 106: 472-482. PMID: 29990835, DOI: 10.1016/j.biopha.2018.06.168.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdaptation, PhysiologicalAnimalsApoptosisApoptosis Regulatory ProteinsAutophagyAutophagy-Related ProteinsBiomarkersCell Cycle ProteinsCell HypoxiaCell ProliferationCellular MicroenvironmentDiabetes Mellitus, ExperimentalDisease ProgressionEnergy MetabolismGene Expression RegulationInflammation MediatorsInsulin-Secreting CellsKineticsMaleRatsConceptsB cellsLymphocytic infiltrationDays of injectionBiphasic patternB cell proliferationOnset of diabetesOvernight fasted ratsProgression of diabetesProgressive diabetesExpression of incretin receptorsInflammatory markersSTZ injectionSTZ administrationProtective markerBiphasic pattern of expressionIncretin receptorsIL-6Pattern of expressionBcl-2Fasted ratsGLP-1RBlood glucoseHIF-1aNF-kBDrug interventionIncretin hormones receptor signaling plays the key role in antidiabetic potential of PTY-2 against STZ-induced pancreatitis
Srivastava S, Shree P, Pandey H, Tripathi Y. Incretin hormones receptor signaling plays the key role in antidiabetic potential of PTY-2 against STZ-induced pancreatitis. Biomedicine & Pharmacotherapy 2017, 97: 330-338. PMID: 29091882, DOI: 10.1016/j.biopha.2017.10.071.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsBinding energyDissociation constantIn silico molecular docking approachPTY-2Molecular docking approachIn silico molecular dockingReceptor agonistsPlasma levelsGIP-RDPPIV inhibitorsPlasma levels of GLP-1Pancreatic expressionDiabetic controlDocking approachGLP-1RLevels of GLP-1Molecular dockingH & E stainingHormone receptor agonistsHormone receptor signalingExpression of GLP-1RExpression of genesSTZ-induced diabetesLesser side effectsComparison to diabetic controlsGLP 1 Regulated Intestinal Cell’s Insulin Expression and Selfadaptation before the Onset of Type 2 Diabetes
Srivastava S, Pandey H, Singh S, Tripathi Y. GLP 1 Regulated Intestinal Cell’s Insulin Expression and Selfadaptation before the Onset of Type 2 Diabetes. Advanced Pharmaceutical Bulletin 2019, 9: 325-330. PMID: 31380261, PMCID: PMC6664108, DOI: 10.15171/apb.2019.039.Peer-Reviewed Original ResearchCitationsConceptsSingle dose of streptozotocinGLP-1Insulin expressionHigh-fat dietCell apoptosisDecreased insulin expressionLevels of GLP-1Groups of diabetic ratsWeeks of high-fat dietDose of streptozotocinGLP-1 levelsIntestinal epithelial cellsB-cell damageIntestinal cell apoptosisIncretin hormone secretionDiabetic control groupDipeptidyl peptidase 4Onset of type 2 diabetesType 2 diabetesGLP-1 analoguesSingle doseDiabetes onsetT2D ratsHormone secretionDiabetic ratsAnti-oxidant, anti-apoptotic, anti-hypoxic and anti-inflammatory conditions induced by PTY-2 against STZ-induced stress in islets
Srivastava S, Pandey H, Singh S, Tripathi Y. Anti-oxidant, anti-apoptotic, anti-hypoxic and anti-inflammatory conditions induced by PTY-2 against STZ-induced stress in islets. BioScience Trends 2019, 13: 382-393. PMID: 31597821, DOI: 10.5582/bst.2019.01181.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsActive phytochemicals of Pueraria tuberosa for DPP-IV inhibition: in silico and experimental approach
Srivastava S, Shree P, Tripathi Y. Active phytochemicals of Pueraria tuberosa for DPP-IV inhibition: in silico and experimental approach. Journal Of Diabetes & Metabolic Disorders 2017, 16: 46. PMID: 29201861, PMCID: PMC5697100, DOI: 10.1186/s40200-017-0328-0.Peer-Reviewed Original ResearchCitationsConceptsOral glucose tolerance testDPP IV activityActive phytochemicalsDPP-IV inhibitionGLP-1Postprandial stateDiabetic modelDPP-IV inhibitory propertiesPueraria tuberosaIntestinal homogenatesLevels of GLP-1Water extractTolerance responseGLP-1 plasma concentrationsSecretion of GLP-1Basal insulin concentrationsGlucose tolerance testDPP-IVCharles Foster ratsComparison to diabetic controlsHPLC-MSControl ratsPotential phytochemicalsFasting bloodBasal insulinRevolutionizing Immunotherapy: Unveiling New Horizons, Confronting Challenges, and Navigating Therapeutic Frontiers in CAR-T Cell-Based Gene Therapies
Srivastava S*, Tyagi A*, Pawar VA*, Khan NH*, Arora K, Verma C†, Kumar V†. Revolutionizing Immunotherapy: Unveiling New Horizons, Confronting Challenges, and Navigating Therapeutic Frontiers in CAR-T Cell-Based Gene Therapies. Immunotargets Ther 2024, 13: 413-433. PMID: 39219644, DOI: 10.2147/ITT.S474659.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsA dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models
Stabach P, Sims D, Gomez-Bañuelos E, Zehentmeier S, Dammen-Brower K, Bernhisel A, Kujawski S, Lopez S, Petri M, Goldman D, Lester E, Le Q, Ishaq T, Kim H, Srivastava S, Kumar D, Pereira J, Yarema K, Koumpouras F, Andrade F, Braddock D. A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models. JCI Insight 2024, 9: e177003. PMID: 38888971, PMCID: PMC11383374, DOI: 10.1172/jci.insight.177003.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSystemic lupus erythematosusDNASE1L3 deficiencySporadic systemic lupus erythematosusAssociated with systemic lupus erythematosusChromatin degradationDNA accumulationDevelopment of lupusPristane-induced lupusSelf-DNACell free DNAHuman isoformsSystemic lupus erythematosus plasmasDouble knockout miceDNASE1L3Pathogenic effectsFree DNALupus modelEnzymeInducible lupus modelAdult patientsLupus erythematosusKnockout micePediatric populationAutoimmune diseasesDNACatalysis-Independent ENPP1 Protein Signaling Regulates Mammalian Bone Mass
Zimmerman K*, Liu X*, von Kroge S*, Stabach P, Lester ER, Chu EY, Srivastava S, Somerman MJ, Tommasini SM, Busse B, Schinke T, Carpenter TO, Oheim R, Braddock DT. Catalysis‐Independent ENPP1 Protein Signaling Regulates Mammalian Bone Mass. Journal Of Bone And Mineral Research 2022, 37: 1733-1749. PMID: 35773783, PMCID: PMC9709593, DOI: 10.1002/jbmr.4640.Peer-Reviewed Original Research
News & Links
Copy Link
News
Get In Touch
Copy Link